Projects
SINCE ITS INCORPORATION THE FOUNDATION HAS AGREED TO SUPPORT:
The Lymphoma Association by funding the cost of local support groups. 
These are made
up of individuals who are, or have been, affected by lymphoma in some way; whether
patient, family member, friend or carer. The aim of a group is to provide mutual
support for members in a form most appropriate for the needs of those members, as
determined by them. Group meetings probably include a variety of medical and non-
The Lymphoma Association Buddy Scheme.
Those with lymphoma can discuss any issues
relating lymphoma and its treatment with another person who has been through a similar
experience. ‘Buddies’ are people who have had lymphoma themselves or have someone
close to them who have had lymphoma. They are not trained counsellors but have volunteered
to offer a listening ear to anyone in need.
__________________________________________________
The British Society for Haematology.
There are few opportunities for academic haematologists
to qualify, partly because the funding costs are so high and it is highly competitive.
This will ultimately give us the improvement in treatment of lymphoma. With the assistance
of the Society we offer a scholarship to potential academic haematologists. All applications
should be made through the Society Secretary quoting ‘The Roger Counter Foundation’.
__________________________________________________
The Royal Free Hospital Haematology Department.
A grant was made to complete the
funding of Phase II of this £120,000 pilot project for writing new software that
will allow the 4 labs involved in the lymphoma screening process to coordinate their
results in a standard format before these are sent back to the consultant. This will
enable the UK to be brought into line with mainstream EU diagnostic systems but more
importantly should allow clinicians to diagnose lymphoma more accurately. Current
research shows that 1 in 3 cases in men in the UK are misdiagnosed leading to premature
death or a failure to treat the fight disease at the optimum time.
__________________________________________________
The CHUV Hospital, Haematology Department Lausanne.
A grant of up to Swiss Francs
165,000 has been earmarked for a Project of the Swiss Group for Clinical Cancer Research.
This is a Phase II multicentre study run from Lausanne to assess the feasibility
and efficacy of the drugs Clofarabine, Gemtuzumab Ozogamicin and doses of Cytarabine
for the treatment of relapsed/refractory AML in young patients.